The CLL-OUTCOME project receives funding from European Partnership for Personalised Medicine

‍

The European Partnership for Personalised Medicine (EP PerMed), supported by the European Union under Horizon Europe, in 2024 launched its first joint transnational call (JTC2024) for proposals on “Identificationor Validation of Targets for Personalised Medicine Approaches (PMTargets)”. Altogether, 45 million Euro were made available through this call.

The project CLL-OUTCOME, Chronic lymphocyticleukemia: Improving survival and quality of life, has now received an allocation of 18 million NOK (1.5 mEuro) over three years. We congratulate Sigrid Skånland, project leader at the Institute for Cancer Research, OUH and researcher in functional precision oncology in MATRIX. CLL-OUTCOME is led by Sigrid Skånland and Oslo University Hospital (OUH), and the project has a total of 7 partners.

The main focus of the project is to tailor the treatment of patients with CLL (chronic lymphocytic leukemia) to prolong survival and improve quality of life. The project is a continuation of the ERA PerMed project CLL-CLUE.

"We are very happy that CLL-OUTCOME receives this funding. It gives us the opportunity to bring the results from CLL-CLUE closer to clinical implementation," says project manager Sigrid Skånland.

‍

CLL-OUTCOME project partners:

·     Sigrid Skånland, Oslo University Hospital (Coordinator)

·     Tero Aittokallio, University of Helsinki, Finland

·     Barbara Eichhorst, University Hospital of Cologne, Germany

·     Carsten Utoft Niemann, Copenhagen University Hospital, Denmark

·     Thorsten Zenz, University of Zurich, Switzerland

·     Carin Uyl-de Groot, Erasmus University Rotterdam, The Netherlands

·     Olav Ljøsne, The Norwegian Blood Cancer and Leukemia Association

‍